
NHS 'failing our most vulnerable' as elderly more likely to wait longer in A&E
A&Es have seen a surge in elderly patients waiting more than 12 hours since the NHS was forced to normalise 'corridor care' to get ambulances back on the road
A&Es have seen a huge surge in elderly patients waiting to be admitted since the normalisation of 'corridor care'. NHS data collated by the Royal College of Emergency Medicine (RCEM) shows the older they are, the more likely they are to have to wait.
Figures obtained under Freedom of Information Act laws show that 1.15 million people aged 60 and over waited more than 12 hours to be transferred, admitted or discharged in England's major A&E departments last year. This is a jump on the 991,068 in 2023 and about three times the figure for 2019, when 305,619 were affected.
Dr Adrian Boyle, president of the RCEM, said: "The healthcare system is failing our most vulnerable patients - more than a million last year. These people are our parents, grandparents, great-grandparents. They aren't receiving the level of care they need, as they endure the longest stays in our emergency departments, often suffering degrading and dehumanising corridor care.
"It's an alarming threat to patient safety. We know long stays are dangerous, especially for those who are elderly, and puts people's lives at risk.'
The research found that the likelihood of experiencing a 12-hour wait in an emergency department increases with the age of the patient. People aged 60 to 69 have a 15% chance of waiting 12 hours or more, whereas for those aged 90 and above, the likelihood rises to 33%.
It comes after the NHS decided to start letting patients into A&E en masse from ambulances queuing outside, even when there is no bed available. Last winter the Mirror reported from the frontline of the NHS 'corridor care' crisis which the Royal College of Nursing said was the worst it has ever been.
A 460-page RCN report in January chronicled testimony from 5,000 nurses which laid bare the consequences of a decade of NHS under-funding with patients spending hours slowly dying on trolleys in busy corridors and a dead patient being found under a pile of coats in a waiting room.
Seven in ten nurses said they were daily delivering care in over-crowded or unsuitable places like corridors, converted cupboards, bathrooms, cloakrooms, paediatric recovery rooms with children in and even car parks - something that had previously been a temporary measure for emergencies.
The RCEM says the NHS data it obtained also suggests older people are missing out on vital checks in A&E. It compiled a Quality Improvement Programme (QIP) study using data from 149 emergency departments involving 24,865 patients. Among patients over 75, the research found insufficient screening for three common conditions which frequently affect older people.
The report found only 16% of patients were screened for delirium - a reversible condition which is linked to increased risk of death and is noted by a sudden change in mental function. On average, fewer than half (48%) of patients were screened for their risk of falls. Just over half (56%) were screening for general frailty - which if picked up early can lead to prompt extra support in hospital and at home.
The report recommended changes, including "front door frailty screening" in every A&E. This is already being introduced across Scotland.
RCEM president Dr Adrian Boyle added: "The healthcare system is failing our most vulnerable patients - more than a million last year. These people are our parents, grandparents, great-grandparents. They aren't receiving the level of care they need, as they endure the longest stays in our emergency departments, often suffering degrading and dehumanising corridor care.
"It's an alarming threat to patient safety. We know long stays are dangerous, especially for those who are elderly, and puts people's lives at risk. As our QIP highlights, more needs to be done to improve their care - vital tests need to get underway as soon as they arrive to inform the care they need and mitigate the risk of another visit to the emergency department.
"There are good pockets of practice, and emergency medicine clinicians are trying their best to deliver the care they need. It's the system that's the issue and will continue to disproportionally affect older people unless governments across the UK make A&E a political priority."
Dr Anu Mitra, project lead of RCEM's care of older people QIP, said: "Older people make up a large proportion of attendances to the emergency department, bringing greater health complexities and evolving care needs. In the backdrop of worsening crowding and increasing long stays, emergency clinicians need to ensure they maintain the basic elements of care and comfort for older patients.
"It's been encouraging to see that, despite the challenging environments emergency medicine clinicians are working in, there has already been improvements in ensuring these patients are receiving the assessments they need. It's vital we continue this work for this vulnerable patient cohort to meet their needs and provide the level of care they deserve."
A Department of Health and Social Care spokesman said: "It is unacceptable that older people are waiting up to 12 hours or more in A&E. This Government is investing £26 billion in the NHS and social care over the next two years, has ended the resident doctor strikes so staff are on the frontline, and is committed to cutting A&E waiting times so patients are seen faster.
"Through our 10-year health plan, we will ensure that patients, including older people, are seen promptly in A&E, waiting times continue to come down, and more people get a GP appointment."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


BBC News
an hour ago
- BBC News
Royal Berkshire Hospital's share of £4.4m funding 'not enough'
Funding awarded to a hospital for repairs and refurbishments is "not enough", a local MP has said. The government announced a £4.4m shared grant for Royal Berkshire Hospital (RBH) and Bracknell Liberal Democrat MP for Wokingham Clive Jones said the cash would "not touch the sides".The government said the funding would prevent appointments being cancelled and blamed "14 years of austerity" from previous administrations for the current problems in the NHS. The hospital, on Craven Road in Reading, was set to be rebuilt under the last government's new hospitals this has been delayed until at least 2037 by the current government, which said the previous plan was not affordable. Jones said the money was "very welcome" but "not enough"."We have £102m shortfall already and it's forecast to be up to £400m in the next 10 to 15 years," he said."So, £4.4m really does not touch the sides."He said he had met with Minister of State for Health Karen Smyth about the matter."Even if they give us £4.4m every year for the next 10 years we've still got a significant shortfall," he continued."I know the minister is well aware of the special circumstances of the Royal Berkshire and that there are parts of it that are 200 years old."Chief executive of RBH Steve McManus said he had also hoped for more funding. He said: "The hospital was in a losing battle against a constant need for repairs, with 50 operations being cancelled in 18 months due to estate disrepair, including power cuts, leaking roofs and collapsed ceilings."A spokesperson from the Department of Health and Social Care said: "We inherited a crumbling NHS following 14 years of austerity, including during the Lib Dems' time in office, but we are determined to turn this around."This week's investment is an essential step to make our hospitals safer and more efficient places to provide care."It added: "These works are funded through the Budget, which provided an extra £26 billion for health and care, and was voted against by the Lib Dems along with every other opposition party. Only Labour will rebuild our broken NHS." You can follow BBC Berkshire on Facebook, X (Twitter), or Instagram.


North Wales Chronicle
an hour ago
- North Wales Chronicle
Alzheimer's blood test ‘can accurately pick up early symptoms'
Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'


South Wales Guardian
an hour ago
- South Wales Guardian
Alzheimer's blood test ‘can accurately pick up early symptoms'
Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'